Two Sigma Advisers’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-186,880
| Closed | -$7.18M | – | 2650 |
|
|
2023
Q2 | $7.18M | Sell |
186,880
-28,000
| -13% | -$719K | 0.02% | 614 |
|
|
2023
Q1 | $4.97M | Sell |
214,880
-22,100
| -9% | -$527K | 0.01% | 809 |
|
|
2022
Q4 | $6.21M | Sell |
236,980
-8,200
| -3% | -$182K | 0.02% | 690 |
|
|
2022
Q3 | $4.82M | Buy |
245,180
+110,700
| +82% | +$2.22M | 0.01% | 751 |
|
|
2022
Q2 | $2.35M | Sell |
134,480
-4,040
| -3% | -$63.4K | 0.01% | 1132 |
|
|
2022
Q1 | $2.27M | Sell |
138,520
-178,400
| -56% | -$2.43M | 0.01% | 1179 |
|
|
2021
Q4 | $5.17M | Sell |
316,920
-62,800
| -17% | -$894K | 0.01% | 753 |
|
|
2021
Q3 | $4.84M | Buy |
379,720
+215,800
| +132% | +$2.84M | 0.01% | 795 |
|
|
2021
Q2 | $2.31M | Buy |
163,920
+74,500
| +83% | +$1.19M | 0.01% | 1223 |
|
|
2021
Q1 | $1.39M | Sell |
89,420
-3,800
| -4% | -$62K | ﹤0.01% | 1461 |
|
|
2020
Q4 | $1.48M | Buy |
93,220
+20,460
| +28% | +$309K | ﹤0.01% | 1403 |
|
|
2020
Q3 | $884K | Sell |
72,760
-2,380
| -3% | -$31.9K | ﹤0.01% | 1555 |
|
|
2020
Q2 | $868K | Buy |
75,140
+3,360
| +5% | +$46.3K | ﹤0.01% | 1646 |
|
|
2020
Q1 | $983K | Sell |
71,780
-920
| -1% | -$10.9K | ﹤0.01% | 1498 |
|
|
2019
Q4 | $429K | Buy |
72,700
+16,960
| +30% | +$92.2K | ﹤0.01% | 1934 |
|
|
2019
Q3 | $295K | Buy |
55,740
+3,640
| +7% | +$24.2K | ﹤0.01% | 1926 |
|
|
2019
Q2 | $401K | Buy |
52,100
+2,660
| +5% | +$40.5K | ﹤0.01% | 1899 |
|
|
2019
Q1 | $984K | Buy |
49,440
+21,620
| +78% | +$377K | ﹤0.01% | 1537 |
|
|
2018
Q4 | $367K | Buy |
27,820
+21,220
| +322% | +$424K | ﹤0.01% | 1895 |
|
|
2018
Q3 | $243K | Sell |
6,600
-720
| -10% | -$23.1K | ﹤0.01% | 2024 |
|
|
2018
Q2 | $256K | Buy |
+7,320
| New | +$281K | ﹤0.01% | 2146 |
|
|
2016
Q1 | – | Sell |
-1,720
| Closed | -$242K | – | 2169 |
|
|
2015
Q4 | $242K | Buy |
+1,720
| New | +$234K | ﹤0.01% | 1593 |
|
Two Sigma Advisers's KDNY Position: Q3 2023 in Review
Two Sigma Advisers sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 186,880 shares — an estimated $7.18M sold.
Two Sigma Advisers first reported a position in KDNY in Q4 2015 and held it in 22 quarters. The position peaked at $7.18M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Two Sigma Advisers reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Two Sigma Advisers sold 186,880 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $7.18M.
- Two Sigma Advisers first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 22 quarters.
- Two Sigma Advisers's Chinook Therapeutics, Inc. Common Stock position peaked at $7.18M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.